FDA Approves CMV Test for Baby Virus Hunt
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting a new test for detecting congenital cytomegalovirus (CMV) into a special safety category called Class II. This means the test will have clear rules to make sure it’s safe and works well, helping doctors and patients get access to this important tool faster. This change affects device makers and healthcare providers and aims to speed up innovation without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Manufacturers Face Class II Rules
If you make medical tests for congenital cytomegalovirus (CMV), the FDA has put the CMV nucleic acid detection device into Class II with special controls. That gives clear, codified safety and performance rules and is intended to reduce regulatory burdens for device makers so innovation can move faster.
Faster Patient Access to CMV Tests
If you are a parent or patient needing congenital CMV testing, the FDA's Class II classification for the CMV nucleic acid detection device is intended to enhance patient access to these diagnostic tests. The agency says the change should help speed innovation and improve access without adding extra costs or delays.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in